Redeye has a positive view of Corline’s new deal with Imperative Care regarding CHS-coating of stroke equipment. In our opinion, the agreement reinforces confidence in the CHS business and highlights Corline's business development efforts in this segment. Without further visibility into the deal, we choose to model a conservative contribution to our sales estimates from the deal, with scope for re-valuation as it progresses into a more commercial stage.